HK1156250A1 - Unit dosage of apadenoson - Google Patents
Unit dosage of apadenosonInfo
- Publication number
- HK1156250A1 HK1156250A1 HK11110662.3A HK11110662A HK1156250A1 HK 1156250 A1 HK1156250 A1 HK 1156250A1 HK 11110662 A HK11110662 A HK 11110662A HK 1156250 A1 HK1156250 A1 HK 1156250A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- apadenoson
- unit dosage
- dosage
- unit
- Prior art date
Links
- 229950001316 apadenoson Drugs 0.000 title 1
- FLEVIENZILQUKB-XTWQNQIISA-N chembl1950649 Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(C#CC[C@@H]3CC[C@H](CC3)C(=O)OC)=NC(N)=C2N=C1 FLEVIENZILQUKB-XTWQNQIISA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7816908P | 2008-07-03 | 2008-07-03 | |
| US15593709P | 2009-02-27 | 2009-02-27 | |
| PCT/US2009/003939 WO2010002473A1 (en) | 2008-07-03 | 2009-07-02 | Unit dosage of apadenoson |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1156250A1 true HK1156250A1 (en) | 2012-06-08 |
Family
ID=41152021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK11110662.3A HK1156250A1 (en) | 2008-07-03 | 2011-10-07 | Unit dosage of apadenoson |
Country Status (24)
| Country | Link |
|---|---|
| US (6) | US20100003193A1 (ru) |
| EP (1) | EP2306971B1 (ru) |
| JP (2) | JP2011526894A (ru) |
| KR (2) | KR20110028531A (ru) |
| CN (1) | CN102119023B (ru) |
| AU (1) | AU2009266317B2 (ru) |
| BR (1) | BRPI0913939A2 (ru) |
| CA (1) | CA2729819C (ru) |
| CY (1) | CY1116283T1 (ru) |
| DK (1) | DK2306971T3 (ru) |
| EA (1) | EA022348B1 (ru) |
| ES (1) | ES2537069T3 (ru) |
| HK (1) | HK1156250A1 (ru) |
| HR (1) | HRP20150454T1 (ru) |
| IL (2) | IL210428A (ru) |
| MX (1) | MX2011000193A (ru) |
| MY (1) | MY161655A (ru) |
| NZ (1) | NZ590489A (ru) |
| PL (1) | PL2306971T3 (ru) |
| PT (1) | PT2306971E (ru) |
| SI (1) | SI2306971T1 (ru) |
| SM (1) | SMT201500123B (ru) |
| WO (1) | WO2010002473A1 (ru) |
| ZA (1) | ZA201100163B (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9415058B2 (en) | 2008-07-03 | 2016-08-16 | University Of Virginia Patent Foundation | Unit dosage of Apadenoson |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013114204A1 (en) | 2012-02-03 | 2013-08-08 | Adenobio N.V. | A method of using adenosine and dipyridamole for pharmacologic stress testing, with specific compositions, unit dosage forms and kits |
| CN109020881B (zh) * | 2018-06-28 | 2020-04-28 | 新发药业有限公司 | 一种阿帕替尼的制备方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5091171B2 (en) | 1986-12-23 | 1997-07-15 | Tristrata Inc | Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use |
| DE69120840T2 (de) * | 1990-02-21 | 1996-11-21 | United Kingdom Government | Supraleiter auf Thalliumbasis substituiert durch seltene Erden |
| IT1263831B (it) | 1993-01-29 | 1996-09-04 | Paolo Chiesi | Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina |
| DK1150991T3 (da) | 1999-02-01 | 2004-06-07 | Univ Virginia | Præparater til behandling af inflammatoriske reaktioner |
| US7427606B2 (en) | 1999-02-01 | 2008-09-23 | University Of Virginia Patent Foundation | Method to reduce inflammatory response in transplanted tissue |
| US6232297B1 (en) * | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
| US6322771B1 (en) * | 1999-06-18 | 2001-11-27 | University Of Virginia Patent Foundation | Induction of pharmacological stress with adenosine receptor agonists |
| US7255934B2 (en) * | 2000-10-23 | 2007-08-14 | National Institute Of Advanced Industrial Science And Technology | Composite structure body and method and apparatus for manufacturing thereof |
| US6620645B2 (en) * | 2000-11-16 | 2003-09-16 | G.T. Equipment Technologies, Inc | Making and connecting bus bars on solar cells |
| SG176313A1 (en) * | 2001-10-01 | 2011-12-29 | Univ Virginia Patent Found | 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof |
| WO2003072597A1 (en) * | 2002-02-27 | 2003-09-04 | Ferring Bv | Intermediates and methods for making heptapeptide oxytocin analogues |
| AU2003234716A1 (en) * | 2002-04-10 | 2003-10-27 | Joel M. Linden | Use of a2a adenosine receptor agonists for the treatment of inflammatory diseases |
| US6662088B1 (en) * | 2002-06-28 | 2003-12-09 | General Electric Company | Methods and systems for inspecting aircraft fuselage frames |
| US7396825B2 (en) * | 2004-05-03 | 2008-07-08 | University Of Virginia Patent Foundation | Agonists of A2A adenosine receptors for treatment of diabetic nephropathy |
| CA2576826C (en) | 2004-08-02 | 2014-09-30 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity |
| EP1729355B1 (en) | 2005-06-03 | 2008-11-19 | STMicroelectronics S.r.l. | Self-aligned process for manufacturing phase change memory cells |
| US7767686B2 (en) | 2006-03-03 | 2010-08-03 | Covidien Ag | Method of using adenosine receptor blockers during tissue ablation |
| DE102006022450A1 (de) | 2006-05-13 | 2007-11-15 | Lanxess Deutschland Gmbh | Wässrige Rußdispersionen für Ink-Jet |
| EP2178369A4 (en) * | 2007-07-17 | 2010-12-15 | Combinatorx Inc | TREATMENTS OF PROLIFERATIVE DISORDERS OF LYMPHOCYTES B |
| TW200905703A (en) * | 2007-07-27 | 2009-02-01 | Delta Electronics Inc | Magnetic device and manufacturing method thereof |
| PT2306971E (pt) | 2008-07-03 | 2015-06-18 | Univ Virginia Patent Found | Dosagem unitária de apadenoson |
-
2009
- 2009-07-02 PT PT97739262T patent/PT2306971E/pt unknown
- 2009-07-02 KR KR1020117002495A patent/KR20110028531A/ko active Application Filing
- 2009-07-02 BR BRPI0913939A patent/BRPI0913939A2/pt not_active Application Discontinuation
- 2009-07-02 US US12/496,949 patent/US20100003193A1/en not_active Abandoned
- 2009-07-02 EP EP09773926.2A patent/EP2306971B1/en active Active
- 2009-07-02 CN CN200980131395.6A patent/CN102119023B/zh not_active Expired - Fee Related
- 2009-07-02 PL PL09773926T patent/PL2306971T3/pl unknown
- 2009-07-02 NZ NZ590489A patent/NZ590489A/xx not_active IP Right Cessation
- 2009-07-02 MY MYPI2010006339A patent/MY161655A/en unknown
- 2009-07-02 AU AU2009266317A patent/AU2009266317B2/en not_active Ceased
- 2009-07-02 SI SI200931189T patent/SI2306971T1/sl unknown
- 2009-07-02 MX MX2011000193A patent/MX2011000193A/es active IP Right Grant
- 2009-07-02 JP JP2011516343A patent/JP2011526894A/ja not_active Withdrawn
- 2009-07-02 ES ES09773926.2T patent/ES2537069T3/es active Active
- 2009-07-02 WO PCT/US2009/003939 patent/WO2010002473A1/en active Application Filing
- 2009-07-02 EA EA201100132A patent/EA022348B1/ru not_active IP Right Cessation
- 2009-07-02 DK DK09773926.2T patent/DK2306971T3/en active
- 2009-07-02 KR KR1020147003142A patent/KR20140021726A/ko not_active Application Discontinuation
- 2009-07-02 CA CA2729819A patent/CA2729819C/en active Active
-
2011
- 2011-01-02 IL IL210428A patent/IL210428A/en not_active IP Right Cessation
- 2011-01-06 ZA ZA2011/00163A patent/ZA201100163B/en unknown
- 2011-10-07 HK HK11110662.3A patent/HK1156250A1/xx not_active IP Right Cessation
-
2012
- 2012-07-09 US US13/544,364 patent/US20130017153A1/en not_active Abandoned
-
2013
- 2013-08-29 JP JP2013177622A patent/JP2013237702A/ja active Pending
- 2013-12-11 US US14/103,130 patent/US9415058B2/en not_active Expired - Fee Related
-
2015
- 2015-04-27 HR HRP20150454TT patent/HRP20150454T1/hr unknown
- 2015-05-14 CY CY20151100432T patent/CY1116283T1/el unknown
- 2015-05-22 SM SM201500123T patent/SMT201500123B/xx unknown
-
2016
- 2016-05-10 IL IL245577A patent/IL245577B/en active IP Right Grant
- 2016-06-13 US US15/181,235 patent/US9662406B2/en active Active
-
2017
- 2017-05-19 US US15/600,303 patent/US20170252463A1/en not_active Abandoned
-
2018
- 2018-07-25 US US16/045,359 patent/US20190022253A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9415058B2 (en) | 2008-07-03 | 2016-08-16 | University Of Virginia Patent Foundation | Unit dosage of Apadenoson |
| US9662406B2 (en) | 2008-07-03 | 2017-05-30 | University Of Virginia Patent Foundation | Unit dosage of apadenoson |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2320907A4 (en) | THERAPEUTIC COMPOUNDS | |
| HRP20171421T1 (hr) | Kruti oblici doziranja bendamustina | |
| GB0909680D0 (en) | Dosage form | |
| EP2268285A4 (en) | THERAPEUTIC COMPOUNDS | |
| GB0806794D0 (en) | Therapeutic compounds | |
| GB0813740D0 (en) | Therapeutic compounds | |
| ZA201102604B (en) | Alkylcyclohexylethers of dihydrotetraazabenzoazulenes | |
| GB0804755D0 (en) | Therapeutic compounds | |
| HK1160925A1 (zh) | 組織蛋白酶 的用途 | |
| EP2427183A4 (en) | THERAPEUTIC COMPOUNDS | |
| GB0803054D0 (en) | Medicament | |
| IL245577B (en) | Dose unit of efdanosone | |
| EP2496704A4 (en) | THERAPEUTIC COMPOUNDS | |
| HK1131039A1 (en) | Pharmaceutical use of sophoricoside | |
| EP2456309A4 (en) | THERAPEUTIC COMPOUNDS | |
| GB0906026D0 (en) | Therapeutic compounds | |
| AU2013257527A1 (en) | Unit dosage of apadenoson | |
| GB0802576D0 (en) | Dosage form | |
| GB0911266D0 (en) | Therapeutic compounds | |
| GB0900712D0 (en) | Therapeutic compounds | |
| GB0916608D0 (en) | Therapeutic compounds | |
| GB0916308D0 (en) | Therapeutic compounds | |
| GB0810952D0 (en) | Therapeutic substances | |
| GB0812816D0 (en) | Therapeutic substances | |
| GB0818712D0 (en) | Therapeutic substances |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20230629 |